ERBB2 and non-small cell lung carcinoma: Interestingly, for the predictive purposes HER2-overexpressing non-squamous NSCLC (defined as scores 2+ and 3+ by immunohistochemistry/IHC/) or non-squamous NSCLC harboring a HER2-activating mutation, were used in this trial.